James Gerson
Director, Cellular Therapy Program, University of Vermont Cancer Center · Robert Larner College of Medicine
Credentials: · · · · · ·
History
Research
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
The Lancet · 2021 · 391 citations
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Nature Medicine · 2022 · 286 citations
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Nature Medicine · 2024 · 238 citations
- SB
25 papers
20 papers
20 papers
19 papers
17 papers
17 papers
11 papers
10 papers · 5 as a fellow
Clinical trials
- 2023–2030
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network